A phase-I, open label clinical trial to assess the safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine manufactured by Serum Institute of India Pvt. Ltd. in healthy Indian adults
Latest Information Update: 20 Jan 2021
Price :
$35 *
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions; First in man
- Sponsors Serum Institute of India
- 07 Jan 2021 Results published in the Vaccine
- 18 Jul 2017 Status changed from not yet recruiting to completed.
- 22 Mar 2017 New trial record